Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Bellicum Pharmaceuticals Stock Forecast NASDAQ:BLCM
Price Target and Analyst Ratings
Wells Fargo & Company does not see either upside or downside right now giving BLCM "Overweight - Equal Weight" on their last update on Oct 30, 2020. The price target was set to $4.50.
Historical Ratings
| Date | Rating | Action | Authority | Current Price | Target Price |
|---|---|---|---|---|---|
| 2020-10-30 | Buy - Neutral | Downgraded by | LADENBURG THALM/SH SH | $3.71 | |
| 2020-10-30 | Overweight - Equal Weight | Downgraded by | Wells Fargo & Company | $3.71 | $4.50 |
BLCM Stock Trend
The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.
Given the current short-term trend, the stock is expected to fall -43.06% during the next 3 months and, with a 90% probability hold a price between $0.95 and $1.17 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2021-11-30 | $1.64 | $1.83 | $2.03 |
| 2021-12-01 | $1.61 | $1.81 | $2.01 |
| 2021-12-02 | $1.59 | $1.79 | $1.98 |
| 2021-12-03 | $1.56 | $1.76 | $1.96 |
| 2021-12-06 | $1.54 | $1.74 | $1.93 |
| 2021-12-07 | $1.51 | $1.71 | $1.91 |
| 2021-12-08 | $1.49 | $1.69 | $1.88 |
| 2021-12-09 | $1.46 | $1.66 | $1.86 |
| 2021-12-10 | $1.44 | $1.64 | $1.84 |
| 2021-12-13 | $1.41 | $1.61 | $1.81 |
| 2021-12-14 | $1.39 | $1.59 | $1.79 |
| 2021-12-15 | $1.36 | $1.56 | $1.76 |
| 2021-12-16 | $1.34 | $1.54 | $1.74 |
| 2021-12-17 | $1.31 | $1.51 | $1.71 |
| 2021-12-20 | $1.29 | $1.49 | $1.69 |
| 2021-12-21 | $1.27 | $1.46 | $1.66 |
| 2021-12-22 | $1.24 | $1.44 | $1.64 |
| 2021-12-23 | $1.22 | $1.41 | $1.61 |
| 2021-12-27 | $1.19 | $1.39 | $1.59 |
| 2021-12-28 | $1.17 | $1.37 | $1.56 |
| 2021-12-29 | $1.14 | $1.34 | $1.54 |
| 2021-12-30 | $1.12 | $1.32 | $1.51 |
| 2021-12-31 | $1.09 | $1.29 | $1.49 |
| 2022-01-03 | $1.07 | $1.27 | $1.46 |
| 2022-01-04 | $1.04 | $1.24 | $1.44 |
| 2022-01-05 | $1.02 | $1.22 | $1.42 |
| 2022-01-06 | $0.99 | $1.19 | $1.39 |
| 2022-01-07 | $0.97 | $1.17 | $1.37 |
| 2022-01-10 | $0.94 | $1.14 | $1.34 |
| 2022-01-11 | $0.92 | $1.12 | $1.32 |
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell trans... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 100 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
